Notes to the editor
ESC Press Office Tel.: +33 (0) 7 8531 2036 Email: press@escardio.org
Follow us on Twitter @ESCardioNews
The hashtag for ESC Congress 2022 is #ESCCongress.
This press release accompanies both a presentation and an ESC press conference at the ESC 2022 Congress. It does not necessarily reflect the views of the European Society of Cardiology.
Acknowledgments: The lead author and presenter of the trial results was Dr. Niklas Dyrby Johansen, Center for Translational Cardiology and Pragmatic Randomized Trials, University of Copenhagen, Denmark.
Funding: The study was funded by Sanofi, who provided the high-dose vaccines for the study and a financial contribution to the remaining costs.
Disclosures: JN was previously employed by Sanofi and may own stock and/or stock options in the company. SS, CS, and MML are full-time employees of Sanofi and may own stock and/or stock options in the company. CSL is Chief Medical Officer at Danske Lægers Vaccinations Service, part of the European LifeCare Group, and has received speaker fees and served on advisory boards for GSK, MSD, Pfizer, Takeda and Valneva. BLC has received consulting fees from Amgen, Cardurion, Corvia, Myokardia, and Novartis. SDS has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, BMS, Celladon, Cytokinetics, Eidos, Gilead, GSK, Ionis, Lilly, Mesoblast, MyoKardia, NIH/NHLBI, Neurotronik, Novartis, Novo Nordisk , Respicardia , Sanofi, Theracos, US2.AI and consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GSK, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros and Puretech Health. LK has received speaker honoraria from Novo Nordisk, Novartis, AstraZeneca, Boehringer Ingelheim, and Bayer. TB-S served as a steering committee member of the Amgen-funded GALACTIC-HF trial and the Boston Scientific-funded LUX-Dx TRENDS trial, served on advisory boards for Sanofi and Amgen, received speaker honoraria from Novartis and Sanofi Pasteur, and has received research grants from GE Healthcare and Sanofi Pasteur. All other authors declare no competing interests.
References and notes
1DANFLU-1 will be discussed during:
2Kwong JC, Schwartz KL, Campitelli MA, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med. 2018; 378: 345-353.
3Kytömaa S, Hegde S, Claggett B, et al. Association of influenza-like illness activity with heart failure hospitalizations: the Atherosclerosis Risk in Communities Study. JAMA Cardiol. 2019; 4: 363-369.
4Chow EJ, Rolfes MA, O’Halloran A, et al. Acute cardiovascular events associated with influenza in hospitalized adults. Ann Intern Med. 2020; 173: 605-613.
5Modin D, Jørgensen ME, Gislason G, et al. Influenza vaccine for heart failure. Circulation. 2019; 139: 575-586.
6Fröbert O, Götberg M, Erlinge D, et al. Influenza vaccination after myocardial infarction: a randomized, double-blind, placebo-controlled, multicenter study. Circulation. 2021; 144: 1476–1484.
7DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose vaccine versus standard-dose influenza vaccine in the elderly. N Engl J Med. 2014; 371: 635-645
8DiazGranados CA, Robertson CA, Talbot HK, et al. Prevention of serious events in adults aged 65 years or older: Comparison of high-dose and standard-dose inactivated influenza vaccines. Vaccine. 2015; 33: 4988-4993.
9Lee JKH, Lam GKL, Shin T, et al. Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigen matching: an updated systematic review and meta-analysis. Vaccine. 2021; 39: A24–A35.
For the European Society of Cardiology
The ESC brings together healthcare professionals from more than 150 countries working to advance cardiovascular medicine and help people live longer and healthier lives.
About ESC Congress 2022
It is the world’s largest gathering of cardiovascular professionals, disseminating cutting-edge science both on-site in Barcelona and online – from 26 to 29 August. Check out the science program. More information is available from the ESC press office at press@escardio.org.
Add Comment